Celgene Corp /de/ (CELG) Files Form 4 Insider Selling : Robert J Hugin Sells 75,000 Shares

Celgene Corp /de/ (CELG): Robert J Hugin , director officer of Celgene Corp /de/ sold 75,000 shares on Jun 20, 2016. The Insider selling transaction was reported by the company on Jun 22, 2016 to the Securities and Exchange Commission. The shares were sold at $100.16 per share for a total value of $7,512,000.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 5, 2016, Gilla Kaplan (director) sold 15,967 shares at $101.84 per share price.On Mar 7, 2016, Michael W Bonney (director) purchased 2,000 shares at $103.01 per share price.Also, On Dec 30, 2015, Ernest Mario (director) sold 40,000 shares at $119.36 per share price.On Dec 28, 2015, Michael D Casey (director) sold 20,000 shares at $122.11 per share price.

Celgene Corporation: On Monday, Jun 20, 2016 heightened volatility was witnessed in Celgene Corporation which led to swings in the share price. The shares opened for trading at $100.24 and hit $101.1 on the upside , eventually ending the session at $99.29, with a gain of 0.56% or 0.55 points. The heightened volatility saw the trading volume jump to 48,92,848 shares. The 52-week high of the share price is $140.72 and the company has a market cap of $76,910 M . The 52-week low of the share price is at $92.98.

Celgene Corporation Money Flow Index Chart

Company has been under the radar of several Street Analysts.Celgene Corporation is Reiterated by Sun Trust Rbsn Humphrey to Buy and the brokerage firm has raised the Price Target to $ 147 from a previous price target of $145 .The Rating was issued on Apr 29, 2016.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.